What is Zacks Research’s Forecast for BHC FY2027 Earnings?

Bausch Health Cos Inc. (NYSE:BHC) – Investment analysts at Zacks Research lowered their FY2027 earnings per share estimates for shares of Bausch Health Cos in a note issued to investors on Wednesday, November 19th. Zacks Research analyst Team now forecasts that the company will earn $3.85 per share for the year, down from their previous forecast of $4.34. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.41 per share.

A number of other equities research analysts have also weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Bausch Health Cos in a report on Wednesday, October 8th. Wall Street Zen raised shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $9.00.

Bausch Health Cos Stock Up 0.7%

Shares of BHC opened at $6.04 on Friday. The firm has a fifty day moving average price of $6.45 and a 200-day moving average price of $6.25. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 141.90. The firm has a market capitalization of $2.24 billion, a P/E ratio of 23.23 and a beta of 0.47. Bausch Health Cos has a 12-month low of $4.25 and a 12-month high of $8.69.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cary Street Partners Financial LLC bought a new stake in shares of Bausch Health Cos in the 1st quarter valued at about $27,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Bausch Health Cos during the first quarter valued at approximately $27,000. Northwestern Mutual Wealth Management Co. increased its holdings in Bausch Health Cos by 6,661.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after buying an additional 5,329 shares during the period. Russell Investments Group Ltd. increased its holdings in Bausch Health Cos by 65.9% during the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after buying an additional 3,106 shares during the period. Finally, Wealthquest Corp bought a new position in Bausch Health Cos in the first quarter worth approximately $58,000. 78.65% of the stock is currently owned by institutional investors.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.